Emcure Pharmaceuticals Q2 FY27: Revenue up 24.3% to ₹28,205 Mn, PAT rises 29.3% to ₹3,251 Mn
Emcure Pharmaceuticals reported Q2 FY27 consolidated results with revenue up 24.3% YoY to ₹28,205 million and PAT up 29.3% to ₹3,251 million. EBITDA grew 30.9% to ₹5,748 million. Domestic business grew 12.0% and international business grew 34.5%.
The announcement of strong quarterly financial results with substantial growth in key financial metrics like revenue and profit is a material event that is likely to impact investor sentiment and the company's stock price.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with margin expansion, indicating strong financial performance.
Emcure Pharmaceuticals Limited announced its consolidated financial results for the second quarter and half-year ended September 30, 2026. The company reported a strong performance with revenue from operations reaching ₹28,205 million for Q2 FY27, marking a 24.3% year-on-year growth. For the half-year ended September 30, 2027, revenue stood at ₹54,009 million, an increase of 23.6%.
EBITDA for the quarter grew by 30.9% to ₹5,748 million, with an EBITDA margin of 20.4%, an expansion of 103 basis points year-on-year. Profit After Tax (PAT) saw a significant rise of 29.3% to ₹3,251 million, with a PAT margin of 11.5%, up by 45 basis points.
The domestic business demonstrated a growth of 12.0% to ₹11,553 million in Q2 FY27 (H1 FY27: ₹22,506 million, up 11.1%), while the international business expanded by 34.5% to ₹16,652 million (H1 FY27: ₹31,503 million, up 34.5%).
Satish Mehta, Chairman, Managing Director and CEO, Emcure Pharmaceuticals Ltd., expressed optimism, stating, "Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings." He added that the company expects business momentum to sustain into H2FY27. R&D investments were approximately 4% of revenue, amounting to ₹1,110 million. Net debt stood at ₹13,171 million as of September 30, 2026.
The Board of Directors met on November 03, 2026, to approve these unaudited financial results for the quarter and half-year ended September 30, 2026.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.